ATE279181T1 - Verwendung von 5ht-6 antagonisten zur behandlung adhd - Google Patents

Verwendung von 5ht-6 antagonisten zur behandlung adhd

Info

Publication number
ATE279181T1
ATE279181T1 AT99942912T AT99942912T ATE279181T1 AT E279181 T1 ATE279181 T1 AT E279181T1 AT 99942912 T AT99942912 T AT 99942912T AT 99942912 T AT99942912 T AT 99942912T AT E279181 T1 ATE279181 T1 AT E279181T1
Authority
AT
Austria
Prior art keywords
antagonists
treat adhd
adhd
treat
subjects
Prior art date
Application number
AT99942912T
Other languages
English (en)
Inventor
Charles Alan Reavill
Carol Routledge
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE279181T1 publication Critical patent/ATE279181T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubricants (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99942912T 1998-08-28 1999-08-25 Verwendung von 5ht-6 antagonisten zur behandlung adhd ATE279181T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9818916.0A GB9818916D0 (en) 1998-08-28 1998-08-28 Use
PCT/EP1999/006218 WO2000012073A1 (en) 1998-08-28 1999-08-25 Use of 5ht-6 antagonists

Publications (1)

Publication Number Publication Date
ATE279181T1 true ATE279181T1 (de) 2004-10-15

Family

ID=10838075

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99942912T ATE279181T1 (de) 1998-08-28 1999-08-25 Verwendung von 5ht-6 antagonisten zur behandlung adhd

Country Status (9)

Country Link
US (2) US6380199B1 (de)
EP (1) EP1107745B1 (de)
JP (1) JP2002523447A (de)
AT (1) ATE279181T1 (de)
AU (1) AU5624699A (de)
DE (1) DE69921156T2 (de)
ES (1) ES2230884T3 (de)
GB (1) GB9818916D0 (de)
WO (1) WO2000012073A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
CN1245400C (zh) * 2000-09-18 2006-03-15 东亚荣养株式会社 N－取代苯并噻唑磺胺衍生物
US7071220B2 (en) 2000-09-18 2006-07-04 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives
CA2428971A1 (en) * 2000-11-14 2003-05-01 New River Pharmaceuticals Inc. Conjugates of a therapeutic agent and a peptide carrier
ITBO20010271A1 (it) * 2001-05-08 2002-11-08 Giuseppe Cannazza Metodo per il trattamento e la prevenzione dei disturbi del sistema nervoso centrale associati ad una alterazione della neurotrasmissione gl
PL366619A1 (en) * 2001-05-11 2005-02-07 Biovitrum Ab Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
US7718650B2 (en) 2001-05-11 2010-05-18 Biovitrum Ab Aryl sulfonamide compounds for treating obesity
EA008476B1 (ru) 2001-06-11 2007-06-29 Биовитрум Аб Замещенные сульфонамиды, способ их получения и их применение в качестве лечебного средства для лечения расстройств цнс, ожирения и диабета типа ii
KR100608417B1 (ko) 2001-08-10 2006-08-02 에프. 호프만-라 로슈 아게 5-ｈｔ6 수용체 친화성을 갖는 아릴설포닐 유도체
ES2307919T3 (es) * 2002-03-27 2008-12-01 Glaxo Group Limited Derivados de quinolina y su uso como ligandos de 5-ht6.
AU2003233231B2 (en) * 2002-05-13 2009-02-26 F. Hoffmann-La Roche Ag Benzoxazine derivatives as 5-HT6 modulators and uses thereof
JP4754821B2 (ja) 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
CA2486989A1 (en) * 2002-06-20 2003-12-31 Biovitrum Ab New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
PT1558582E (pt) 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
US7772240B2 (en) 2003-08-18 2010-08-10 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
PT1667975E (pt) * 2003-09-26 2008-02-29 Glaxo Group Ltd Forma polimórfica de 3-fenilsulfonil-8-piperazin-1-il-quinolina
WO2006016278A1 (en) * 2004-08-09 2006-02-16 Warner-Lambert Company Llc Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
EP1973876A2 (de) 2006-01-13 2008-10-01 Wyeth Sulfonylsubstituierte 1h-indole als liganden für 5-hydroxytryptamin-rezeptoren
ES2389958T3 (es) * 2007-03-21 2012-11-05 Glaxo Group Limited Uso de derivados de quinolina en el tratamiento del dolor
US7939520B2 (en) * 2007-05-15 2011-05-10 Wyeth Llc Aminoazacyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
PA8802201A1 (es) 2007-11-02 2009-06-23 Abbott Gmbh & Co Kg Compuestos de bencensulfonalida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6
EP2254564A1 (de) 2007-12-12 2010-12-01 Glaxo Group Limited Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
UA100192C2 (en) * 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
US8343959B2 (en) 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
CA2759491A1 (en) * 2009-04-30 2010-11-04 Abbott Gmbh & Co. Kg. Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
CN102459197B (zh) 2009-04-30 2015-08-19 Abbvie公司 适用于治疗响应血清素5-ht6受体的调节的病症的n-苯基-(哌嗪基或高哌嗪基)-苯磺酰胺或苯磺酰基-苯基-(哌嗪或高哌嗪)化合物
MX2011011515A (es) 2009-04-30 2012-01-30 Abbott Gmbh & Co Kg Compuestos de bencensulfonanilida adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6.
WO2012059432A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor
WO2012059431A1 (en) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
WO2013055386A2 (en) 2011-10-03 2013-04-18 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
US20160038484A1 (en) * 2013-04-03 2016-02-11 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
KR20180064373A (ko) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
DE69921156D1 (de) 2004-11-18
EP1107745B1 (de) 2004-10-13
GB9818916D0 (en) 1998-10-21
DE69921156T2 (de) 2005-10-13
US6627661B2 (en) 2003-09-30
EP1107745A1 (de) 2001-06-20
US20020094979A1 (en) 2002-07-18
WO2000012073A1 (en) 2000-03-09
JP2002523447A (ja) 2002-07-30
AU5624699A (en) 2000-03-21
US6380199B1 (en) 2002-04-30
ES2230884T3 (es) 2005-05-01

Similar Documents

Publication Publication Date Title
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69805202D1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
ATE249220T1 (de) Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
NO984189L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE60020591D1 (de) Benzenoidderivate von 15-hydroxyeicosatetraensäure und verfahren zur verwendung zur behandlung des trockenen auges
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties